Relaxin: antifibrotic properties and effects in models of disease

Area of Science:

• Biomedical Science
• Endocrinology
• Pathology

Background:

• Fibrosis, characterized by excessive connective tissue, is a major cause of organ failure globally.
• Current treatments for fibrosis are limited, necessitating novel therapeutic approaches.
• Relaxin, a pleiotropic hormone, is recognized for its potential antifibrotic properties.

Purpose of the Study:

• To review the mechanisms by which relaxin inhibits collagen production and degradation in fibrotic models.
• To examine the collagen-related phenotypes in mice lacking relaxin or its receptor (LGR7).
• To evaluate the therapeutic potential of relaxin in managing fibrosis.

Main Methods:

• Review of existing literature on relaxin's effects on collagen synthesis and degradation.
• Analysis of data from studies involving induced fibrosis models.
• Examination of genetic studies using relaxin- and LGR7-deficient mouse models.

Main Results:

• Relaxin effectively limits collagen production and reorganization while promoting collagen degradation.
• Studies demonstrate relaxin's ability to prevent fibrogenesis and reduce existing scar tissue.
• Relaxin-deficient mice exhibit altered collagen turnover, underscoring relaxin's regulatory role.

Conclusions:

• Relaxin emerges as a significant endogenous regulator of collagen turnover.
• Relaxin exhibits potent antifibrotic effects, offering therapeutic potential for various fibrotic conditions.
• Further research into relaxin-based therapies could lead to effective treatments for organ fibrosis.